- Email: [email protected]
129 An audit of a single center use of SABR in primary lung cancer patients
S46
126
Poster abstracts of the 14th Annual British Thoracic Oncology Group Conference 2016 / Lung Cancer 91, Suppl. 1 (2016) S1–S71
CyberKnife® for early stage non-small cell lung cancer (NSCLC) at a tertiary referral centre – results of the first two years of treatment at Birmingham
V. Sangha 1 , R. Stevenson 2 , V. Harrop 2 , G. Heyes 2 , H. Howard 2 , A. Kapadia 2 , Q. Ghafoor 2 . 1 Oncology Department, Queen Elizabeth Hospital, Birmingham, United Kingdom; 2 Queen Elizabeth Hospital, Birmingham, United Kingdom Introduction: Linac-based 4D Stereotactic Ablative Body Radiotherapy (SABR) was introduced at UHB in May 2013 and has now treated 83 patients. The CyberKnife® is a frameless stereotactic radiotherapy system that involves a light-weight 6MV linear accelerator mounted on a highly mobile robotic arm with real time image guidance system. We describe our experience of the first 26 patients treated with this new technique. Methods: Patients eligible for SABR were selected via lung MDT. Patients with tumours ≥2cm trackable with a minimum of “2 views” underwent CyberKnife® treatment. Prospective data collected between June 2014 and July 2015 included patient demographics, surgical contra-indications and clinical/radiological follow up. The dosefractionations delivered were those stipulated in the UK SABR Consortium guidance (54Gy/3#; 55Gy/5#, 60Gy/8). The ITV to PTV margins when treated with the CyberKnife® are reduced to 3mm from the 5mm used with Linac-based SABR. Results: 22 patients with medically inoperable early stage primary NSCLC and 2 by patient choice were treated with the CyberKnife® . Without treatment, 15 of the 24 patients would receive best supportive care; the others radical radiotherapy. 2 patients were deemed unsuitable for the CyberKnife® due to patient deterioration and tumour encroachment onto the no fly zone. 23 CXR responses were evaluated 6 weeks post-treatment; 22 achieving a partial response (PR) and 1 possible progression. 3 month CT follow-up reported 17 maintaining PR, 1 metastasising elsewhere in the lung and 1 confirmed as local progression on PET-CT. Side-effects included 8 cases of grade 1 cough, 2 grade 2 lethargy, 1 grade 3 pneumonitis requiring hospital admission and 1 grade 3 dyspnoea due to progressive disease. 3 patients have died since treatment, 1 from pneumonia, 1 having progressed and 1 unknown. Conclusion: Our data confirms good response rates to treatment with CyberKnife® exhibiting mostly minor side effects and forms a good basis for further exploration. Disclosure: All authors have declared no conflicts of interest. 127
Outcome of CyberKnife radiosurgery for early stage lung cancer
B. Mahmood, J. Conibear, P. Wells. Oncology, Bart’s health, London, United Kingdom Introduction: The aims of this study were to determine if imageguided robotic stereotactic radiosurgery by CyberKnife Radiosurgery System using ablative radiation doses achieves acceptable local control in patients with early non-small-cell lung cancer (NSCLC) and to evaluate disease-free survival, toxicity, and failure. CyberKnife can deliver the prescribed dose by using many different angles converging on the target, with real-time target tracking. Methods: A review of treatment details and outcomes for 24 patients, ranging in age from 49 to 95 years, with histologically proven cancers treated by image-guided robotic stereotactic radiosurgery at the CyberKnife Centre of Barts health between January 2012 and June 2015 is presented. Target localization and respiratory movement compensation were accomplished using a single fiducial marker placed within the tumour, and the X-Sight systems. Total doses ranged from 42 Gy to 60 Gy delivered in 3–5 fractions. Results: Of the 24 patients treated 20 (83%) were still alive at the time of analysis. All patients tolerated the radiosurgery well with no respiratory toxicities. One patient with stage II (T2 N0 M0) small cell
lung cancer recurrence 6 months from initial treatment following initial control of disease has had further chemotherapy and still alive two years later. 4 patients have died from other cause than the cancer progression, 2 of them died as result of exacerbation of chronic obstructive pulmonary disease (COPD), 2 patients died with chest infection. Conclusion: The results indicate that the delivery of precisely targeted ablative radiation of lung in a hypo fractionated fashion is feasible and safe even in those patients with very poor lung function. Image-guided robotic stereotactic radiosurgery of lung tumours with CyberKnife achieves excellent rates of local disease control with limited toxicity to surrounding tissues and, in many cases, might be curative for patients for whom surgery is not an option. Disclosure: All authors have declared no conflicts of interest. 128
A study comparing lung SABR plans generated using Multiplan for CyberKnife and Monaco for Elekta Versa 6FFF
K. Dalling, Q. Ghafoor, S. Watkins, T. Jackson. Radiotherapy Physics, University Hospitals Birmingham, Birmingham, United Kingdom Introduction: Patients at University Hospitals Birmingham receiving lung SABR are treated on either CyberKnife or conventional linac (Elekta Versa 6FFF). Patients are treated with the same fractionation schedules on both machines and identical plan assessment criteria are used. This study aims to look at the differences in what can be achieved on the two platforms. Methods: Patients originally planned using Multiplan for CyberKnife were identified and alternative plans were generated in Monaco for Elekta Versa HD (6FFF). CyberKnife patients are scanned in breath hold. Two scans are acquired: maximum inhale and maximum exhale. Treatment plans are generated on the maximum exhale scan and patients are treated in free breathing while tracking tumour motion. Patients treated on a conventional linac have a 4DCT scan, volumes are delineated on the maximum intensity projection and the plan is calculated on the average intensity projection. In order to replan the CyberKnife patients in a similar manner to the current linac based practice a mobile GTV was outlined on the maximum exhale scan, using the maximum inhale as guidance for the range of tumour motion. This mobile GTV was expanded uniformly to a PTV and a clinically acceptable treatment plan was generated using a 6FFF beam model. Analysis and comparison of DVH data between the two plans was carried out. Results: A total of 10 patients treated on CyberKnife were identified for this study. Plans were generated in Monaco for each of these patients and DVH comparisons were carried out. The significance of any differences found was analysed using a Wilcoxon test. (N.B. At the time of writing not all plans were completed.) Conclusion: This study has allowed us to reflect on the differences in what can be achieved between the two planning and delivery platforms of CyberKnife (Multiplan) and Elekta Versa HD 6FFF (Monaco) for patients treated with SABR for lung cancer. Disclosure: All authors have declared no conflicts of interest. 129
An audit of a single center use of SABR in primary lung cancer patients
K.A. Johnson 1 , S.U. Rahman 2 , T. Sridhar 2 , S. Savory 2 , L. AznarGarcia 2 . 1 Cancer Studies, University of Leicester, Leicester, United Kingdom; 2 Oncology, University of Leicester Hospitals, Leicester, United Kingdom Introduction: SABR for primary lung cancer is becoming increasingly used as evidence is mounting for its comparable long-term clinical outcomes compared to surgery and good overall tolerability. We review our practice against the 2015 SABR consortium guidelines and the follow up of these patients.
Poster abstracts of the 14th Annual British Thoracic Oncology Group Conference 2016 / Lung Cancer 91, Suppl. 1 (2016) S1–S71
S47
Abstract 129 – Table 1 AGE Audit compliance SEX Audit compliance Baseline PS
Audit compliance Comorbidities
Audit compliance FEV1 Predicted FEV1 Audit compliance Position of primary
Audit compliance
78.36 years (median) N/A Male Female N/A 0 1 2
<3 1 2 ≥3 N/A 1.33L 71.1% N/A LUL LLL RUL RML RLL >2cm from proximal bronchial tree
Range: 57–88 years 15 (53.6%) 13 (46.4%) 2 (7.1%) 16 (57.1%) 10 (35.7%) 100% 0 3 (10.7%) 25 (89.3%) Mean – 3.18 0.55–2.38L 38.0–128.0% 14 (50.0%) 3 (10.7%) 7 (25.0%) 3 (10.7%) 1 (3.6%) 100%
Methods: Patients treated with SABR in Leicester for primary lung cancer between January 2014 and August 2015 were included in this study. They were planned using free breathing 4D CT then treated using VMAT. Baseline data was retrospectively collected by a clinical oncologist from radiotherapy notes. Patients were followed up at 4 weeks then at 3 monthly intervals until 1 year. CT scans were performed 3 and 12 months post radiotherapy. Prospective data collection was performed at follow up visits for clinical outcomes and acute and late normal tissue toxicity (scored using CTCAE v 3.0). Results: 28 patients were included in this audit. Summary of demographic and treatment related data is given in Table 1. 100% of patients met inclusion and exclusion criteria as per SABR consortium guidelines. 19 patients have attended post radiotherapy CT scans with 84.2% showing radiological response as per RECIST. All patients were assessed for acute toxicity data, 3.5% (1/28) noted grade two reaction. Data on late toxicity was available for 19 patients: 26.3% (5/19) experienced grade two or more toxicity. When late reactions were adjusted for baseline function (late toxicity score minus baseline score) this fell to 15% (3/19). Conclusion: In our center patients referred for SABR are mainly elderly with multiple pre-existing comorbidities. Despite this we are achieving radiological response in most patients with low rates of moderate or severe toxicity. We are compliant with SABR consortium guidelines. We will continue to collect follow up data on the patients treated to provide data on longer term toxicities and clinical outcomes. Disclosure: All authors have declared no conflicts of interest. 130
Stereotactic ablative body radiotherapy (SABR): Weston Park Hospital experience
T.S. Das, E. Bates, A. Waweru, P. Fisher, C.E. Lee, M. Hatton. Clinical Oncology, Weston Park Hospital, Sheffield, United Kingdom Introduction: SABR is an established radical treatment option for early stage Non-Small Cell Lung Cancer (NSCLC) in the UK. In October 2014 a NHS England’s directive centralised SABR treatment to one centre within the Yorkshire region. This required Weston Park Hospital to refer eligible patients from the North Trent region to Leeds for their SABR treatment. The North Trent SABR MDT remained functional and we have reviewed the treatment patterns for the patients discussed. Methods: The North Trent SABR MDT database has records of all patients referred and discussed since early 2014 with the local SABR treatment program opening in July 2014. We have analysed the data for 63 consecutive NSCLC patients eligible for SABR treatment be-
Longest diameter Audit compliance Stage
Audit compliance PET SUV Audit compliance Histology
Audit compliance Previous treatment Audit compliance Radiotherapy schedule
Audit compliance
18.1mm (mean) Primary <5cm T1aN0M0 T1bN0M0 T2aN0M0
Range: 6.0–40.0mm 100% 20 (71.4%) 6 (21.4%) 2 (7.1%) 100% 26 (92.9%) 2 (7.1%) Range: 1.40–23.4 100% 8 (28.6%) 0 1 (3.6%) 19 (67.9%) 2 (7.1%) 7 (25%) 100% 20 (71.4%) 7 (25%) 1 (3.6%) 100%
tween July 2014 and September 2015 using case notes to provide supplementary information. Results: Of the 63 patients, 32 were women (age range 59–86 (median 73) years). Majority of patients had a WHO Performance status of 2. 39% of patients had a histopathology diagnosis and all had PET scan as pre-treatment staging work-up. 49 patients were reviewed after October 2014 and offered a referral to Leeds, 25 (51%) patients opted to undergo radical radiotherapy locally. Of these 25 patients, 14 received CHART (54Gy in 36 fractions over 12 days) and 3 received Conventional radiotherapy (55Gy in 20 fractions). 16 (64%) patients are currently alive without evidence of disease progression. In comparison 38 patients opted for SABR in Leeds, 1 died before starting treatment and 29 (76%) patients are alive without disease progression. Conclusion: Our experience shows a significant number of patients were unwilling to travel and had a clear preference to undergo local treatment in the knowledge that outcomes might be inferior. However, with the relatively small numbers and short follow up period we are not able to draw that conclusion. Disclosure: All authors have declared no conflicts of interest. 131
Preliminary results of prospective data for patients receiving stereotactic ablative radiotherapy (SABR) for early stage non-small cell lung cancer (NSCLC)
R.L. Pickles, S. Iqbal, P. Atherton, H. Turnbull, R. Mcmenemin, C. Walker, K. Pilling, M. Muller, J. Mott, H. Mccallum. Radiotherapy, Northern centre for Cancer care, Newcastle Upon Tyne, United Kingdom Introduction: SABR is considered a standard of care for medically inoperable early stage NSCLC. The Northern Centre for Cancer Care (NCCC) implemented SABR in June 2014 and have treated 77 patients to date. The toxicity and outcome data was collected prospectively as per the UK SABR consortium guidelines, although the service is still in its infancy. The poster will demonstrate the preliminary clinical data we have collected and SABR techniques utilised. Methods: Data from June 2014 to October 2015 was collected from the SABR database, mosaiq oncology system, diadem, ICE and patient notes. Data included; Demographics, disease characteristics, treatment specifications and the outcome based on results of 6-week, 3month chest xray and 6-month CT scan In addition radiation acute toxicities at 10 day post SABR and retrospective data from peripheral clinic follow up were included. Patients were reviewed utilising CTCV04 criteria. Results: 94 patients were consented for SABR; 77 patients proceeded with treatment on the Varian truebeam STX; including the use of
126
Poster abstracts of the 14th Annual British Thoracic Oncology Group Conference 2016 / Lung Cancer 91, Suppl. 1 (2016) S1–S71
CyberKnife® for early stage non-small cell lung cancer (NSCLC) at a tertiary referral centre – results of the first two years of treatment at Birmingham
V. Sangha 1 , R. Stevenson 2 , V. Harrop 2 , G. Heyes 2 , H. Howard 2 , A. Kapadia 2 , Q. Ghafoor 2 . 1 Oncology Department, Queen Elizabeth Hospital, Birmingham, United Kingdom; 2 Queen Elizabeth Hospital, Birmingham, United Kingdom Introduction: Linac-based 4D Stereotactic Ablative Body Radiotherapy (SABR) was introduced at UHB in May 2013 and has now treated 83 patients. The CyberKnife® is a frameless stereotactic radiotherapy system that involves a light-weight 6MV linear accelerator mounted on a highly mobile robotic arm with real time image guidance system. We describe our experience of the first 26 patients treated with this new technique. Methods: Patients eligible for SABR were selected via lung MDT. Patients with tumours ≥2cm trackable with a minimum of “2 views” underwent CyberKnife® treatment. Prospective data collected between June 2014 and July 2015 included patient demographics, surgical contra-indications and clinical/radiological follow up. The dosefractionations delivered were those stipulated in the UK SABR Consortium guidance (54Gy/3#; 55Gy/5#, 60Gy/8). The ITV to PTV margins when treated with the CyberKnife® are reduced to 3mm from the 5mm used with Linac-based SABR. Results: 22 patients with medically inoperable early stage primary NSCLC and 2 by patient choice were treated with the CyberKnife® . Without treatment, 15 of the 24 patients would receive best supportive care; the others radical radiotherapy. 2 patients were deemed unsuitable for the CyberKnife® due to patient deterioration and tumour encroachment onto the no fly zone. 23 CXR responses were evaluated 6 weeks post-treatment; 22 achieving a partial response (PR) and 1 possible progression. 3 month CT follow-up reported 17 maintaining PR, 1 metastasising elsewhere in the lung and 1 confirmed as local progression on PET-CT. Side-effects included 8 cases of grade 1 cough, 2 grade 2 lethargy, 1 grade 3 pneumonitis requiring hospital admission and 1 grade 3 dyspnoea due to progressive disease. 3 patients have died since treatment, 1 from pneumonia, 1 having progressed and 1 unknown. Conclusion: Our data confirms good response rates to treatment with CyberKnife® exhibiting mostly minor side effects and forms a good basis for further exploration. Disclosure: All authors have declared no conflicts of interest. 127
Outcome of CyberKnife radiosurgery for early stage lung cancer
B. Mahmood, J. Conibear, P. Wells. Oncology, Bart’s health, London, United Kingdom Introduction: The aims of this study were to determine if imageguided robotic stereotactic radiosurgery by CyberKnife Radiosurgery System using ablative radiation doses achieves acceptable local control in patients with early non-small-cell lung cancer (NSCLC) and to evaluate disease-free survival, toxicity, and failure. CyberKnife can deliver the prescribed dose by using many different angles converging on the target, with real-time target tracking. Methods: A review of treatment details and outcomes for 24 patients, ranging in age from 49 to 95 years, with histologically proven cancers treated by image-guided robotic stereotactic radiosurgery at the CyberKnife Centre of Barts health between January 2012 and June 2015 is presented. Target localization and respiratory movement compensation were accomplished using a single fiducial marker placed within the tumour, and the X-Sight systems. Total doses ranged from 42 Gy to 60 Gy delivered in 3–5 fractions. Results: Of the 24 patients treated 20 (83%) were still alive at the time of analysis. All patients tolerated the radiosurgery well with no respiratory toxicities. One patient with stage II (T2 N0 M0) small cell
lung cancer recurrence 6 months from initial treatment following initial control of disease has had further chemotherapy and still alive two years later. 4 patients have died from other cause than the cancer progression, 2 of them died as result of exacerbation of chronic obstructive pulmonary disease (COPD), 2 patients died with chest infection. Conclusion: The results indicate that the delivery of precisely targeted ablative radiation of lung in a hypo fractionated fashion is feasible and safe even in those patients with very poor lung function. Image-guided robotic stereotactic radiosurgery of lung tumours with CyberKnife achieves excellent rates of local disease control with limited toxicity to surrounding tissues and, in many cases, might be curative for patients for whom surgery is not an option. Disclosure: All authors have declared no conflicts of interest. 128
A study comparing lung SABR plans generated using Multiplan for CyberKnife and Monaco for Elekta Versa 6FFF
K. Dalling, Q. Ghafoor, S. Watkins, T. Jackson. Radiotherapy Physics, University Hospitals Birmingham, Birmingham, United Kingdom Introduction: Patients at University Hospitals Birmingham receiving lung SABR are treated on either CyberKnife or conventional linac (Elekta Versa 6FFF). Patients are treated with the same fractionation schedules on both machines and identical plan assessment criteria are used. This study aims to look at the differences in what can be achieved on the two platforms. Methods: Patients originally planned using Multiplan for CyberKnife were identified and alternative plans were generated in Monaco for Elekta Versa HD (6FFF). CyberKnife patients are scanned in breath hold. Two scans are acquired: maximum inhale and maximum exhale. Treatment plans are generated on the maximum exhale scan and patients are treated in free breathing while tracking tumour motion. Patients treated on a conventional linac have a 4DCT scan, volumes are delineated on the maximum intensity projection and the plan is calculated on the average intensity projection. In order to replan the CyberKnife patients in a similar manner to the current linac based practice a mobile GTV was outlined on the maximum exhale scan, using the maximum inhale as guidance for the range of tumour motion. This mobile GTV was expanded uniformly to a PTV and a clinically acceptable treatment plan was generated using a 6FFF beam model. Analysis and comparison of DVH data between the two plans was carried out. Results: A total of 10 patients treated on CyberKnife were identified for this study. Plans were generated in Monaco for each of these patients and DVH comparisons were carried out. The significance of any differences found was analysed using a Wilcoxon test. (N.B. At the time of writing not all plans were completed.) Conclusion: This study has allowed us to reflect on the differences in what can be achieved between the two planning and delivery platforms of CyberKnife (Multiplan) and Elekta Versa HD 6FFF (Monaco) for patients treated with SABR for lung cancer. Disclosure: All authors have declared no conflicts of interest. 129
An audit of a single center use of SABR in primary lung cancer patients
K.A. Johnson 1 , S.U. Rahman 2 , T. Sridhar 2 , S. Savory 2 , L. AznarGarcia 2 . 1 Cancer Studies, University of Leicester, Leicester, United Kingdom; 2 Oncology, University of Leicester Hospitals, Leicester, United Kingdom Introduction: SABR for primary lung cancer is becoming increasingly used as evidence is mounting for its comparable long-term clinical outcomes compared to surgery and good overall tolerability. We review our practice against the 2015 SABR consortium guidelines and the follow up of these patients.
Poster abstracts of the 14th Annual British Thoracic Oncology Group Conference 2016 / Lung Cancer 91, Suppl. 1 (2016) S1–S71
S47
Abstract 129 – Table 1 AGE Audit compliance SEX Audit compliance Baseline PS
Audit compliance Comorbidities
Audit compliance FEV1 Predicted FEV1 Audit compliance Position of primary
Audit compliance
78.36 years (median) N/A Male Female N/A 0 1 2
<3 1 2 ≥3 N/A 1.33L 71.1% N/A LUL LLL RUL RML RLL >2cm from proximal bronchial tree
Range: 57–88 years 15 (53.6%) 13 (46.4%) 2 (7.1%) 16 (57.1%) 10 (35.7%) 100% 0 3 (10.7%) 25 (89.3%) Mean – 3.18 0.55–2.38L 38.0–128.0% 14 (50.0%) 3 (10.7%) 7 (25.0%) 3 (10.7%) 1 (3.6%) 100%
Methods: Patients treated with SABR in Leicester for primary lung cancer between January 2014 and August 2015 were included in this study. They were planned using free breathing 4D CT then treated using VMAT. Baseline data was retrospectively collected by a clinical oncologist from radiotherapy notes. Patients were followed up at 4 weeks then at 3 monthly intervals until 1 year. CT scans were performed 3 and 12 months post radiotherapy. Prospective data collection was performed at follow up visits for clinical outcomes and acute and late normal tissue toxicity (scored using CTCAE v 3.0). Results: 28 patients were included in this audit. Summary of demographic and treatment related data is given in Table 1. 100% of patients met inclusion and exclusion criteria as per SABR consortium guidelines. 19 patients have attended post radiotherapy CT scans with 84.2% showing radiological response as per RECIST. All patients were assessed for acute toxicity data, 3.5% (1/28) noted grade two reaction. Data on late toxicity was available for 19 patients: 26.3% (5/19) experienced grade two or more toxicity. When late reactions were adjusted for baseline function (late toxicity score minus baseline score) this fell to 15% (3/19). Conclusion: In our center patients referred for SABR are mainly elderly with multiple pre-existing comorbidities. Despite this we are achieving radiological response in most patients with low rates of moderate or severe toxicity. We are compliant with SABR consortium guidelines. We will continue to collect follow up data on the patients treated to provide data on longer term toxicities and clinical outcomes. Disclosure: All authors have declared no conflicts of interest. 130
Stereotactic ablative body radiotherapy (SABR): Weston Park Hospital experience
T.S. Das, E. Bates, A. Waweru, P. Fisher, C.E. Lee, M. Hatton. Clinical Oncology, Weston Park Hospital, Sheffield, United Kingdom Introduction: SABR is an established radical treatment option for early stage Non-Small Cell Lung Cancer (NSCLC) in the UK. In October 2014 a NHS England’s directive centralised SABR treatment to one centre within the Yorkshire region. This required Weston Park Hospital to refer eligible patients from the North Trent region to Leeds for their SABR treatment. The North Trent SABR MDT remained functional and we have reviewed the treatment patterns for the patients discussed. Methods: The North Trent SABR MDT database has records of all patients referred and discussed since early 2014 with the local SABR treatment program opening in July 2014. We have analysed the data for 63 consecutive NSCLC patients eligible for SABR treatment be-
Longest diameter Audit compliance Stage
Audit compliance PET SUV Audit compliance Histology
Audit compliance Previous treatment Audit compliance Radiotherapy schedule
Audit compliance
18.1mm (mean) Primary <5cm T1aN0M0 T1bN0M0 T2aN0M0
Range: 6.0–40.0mm 100% 20 (71.4%) 6 (21.4%) 2 (7.1%) 100% 26 (92.9%) 2 (7.1%) Range: 1.40–23.4 100% 8 (28.6%) 0 1 (3.6%) 19 (67.9%) 2 (7.1%) 7 (25%) 100% 20 (71.4%) 7 (25%) 1 (3.6%) 100%
tween July 2014 and September 2015 using case notes to provide supplementary information. Results: Of the 63 patients, 32 were women (age range 59–86 (median 73) years). Majority of patients had a WHO Performance status of 2. 39% of patients had a histopathology diagnosis and all had PET scan as pre-treatment staging work-up. 49 patients were reviewed after October 2014 and offered a referral to Leeds, 25 (51%) patients opted to undergo radical radiotherapy locally. Of these 25 patients, 14 received CHART (54Gy in 36 fractions over 12 days) and 3 received Conventional radiotherapy (55Gy in 20 fractions). 16 (64%) patients are currently alive without evidence of disease progression. In comparison 38 patients opted for SABR in Leeds, 1 died before starting treatment and 29 (76%) patients are alive without disease progression. Conclusion: Our experience shows a significant number of patients were unwilling to travel and had a clear preference to undergo local treatment in the knowledge that outcomes might be inferior. However, with the relatively small numbers and short follow up period we are not able to draw that conclusion. Disclosure: All authors have declared no conflicts of interest. 131
Preliminary results of prospective data for patients receiving stereotactic ablative radiotherapy (SABR) for early stage non-small cell lung cancer (NSCLC)
R.L. Pickles, S. Iqbal, P. Atherton, H. Turnbull, R. Mcmenemin, C. Walker, K. Pilling, M. Muller, J. Mott, H. Mccallum. Radiotherapy, Northern centre for Cancer care, Newcastle Upon Tyne, United Kingdom Introduction: SABR is considered a standard of care for medically inoperable early stage NSCLC. The Northern Centre for Cancer Care (NCCC) implemented SABR in June 2014 and have treated 77 patients to date. The toxicity and outcome data was collected prospectively as per the UK SABR consortium guidelines, although the service is still in its infancy. The poster will demonstrate the preliminary clinical data we have collected and SABR techniques utilised. Methods: Data from June 2014 to October 2015 was collected from the SABR database, mosaiq oncology system, diadem, ICE and patient notes. Data included; Demographics, disease characteristics, treatment specifications and the outcome based on results of 6-week, 3month chest xray and 6-month CT scan In addition radiation acute toxicities at 10 day post SABR and retrospective data from peripheral clinic follow up were included. Patients were reviewed utilising CTCV04 criteria. Results: 94 patients were consented for SABR; 77 patients proceeded with treatment on the Varian truebeam STX; including the use of